Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results source : Ir.biolinerx.com save search
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Published: 2023-08-30 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 8.27%
H: 0.69%
C: -3.47%
financial results
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Published: 2023-05-24 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 2.67%
H: 1.95%
C: 1.3%
financial results
BioLineRx Reports 2022 Financial Results and Recent Corporate and Portfolio Updates
Published: 2023-03-22 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 0.45%
H: 7.97%
C: 2.7%
financial results
BioLineRx to Report 2022 Annual Financial Results on March 22, 2023
Published: 2023-03-15 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -0.67%
H: 3.17%
C: 2.18%
report financial results
BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors
Published: 2022-12-20 (Crawled : 12:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 1.5%
H: 0.0%
C: -5.43%
agi-134 vaccine tumors results study phase 1
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
Published: 2022-11-15 (Crawled : 12:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -0.5%
H: 0.03%
C: -4.23%
financial results
BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Published: 2022-08-16 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -0.52%
H: 0.0%
C: -5.79%
update results
BioLineRx to Report Second Quarter 2022 Results on August 16, 2022
Published: 2022-08-11 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -1.18%
H: 6.58%
C: 4.76%
report results
BioLineRx to Report First Quarter 2022 Results on May 11, 2022
Published: 2022-05-05 (Crawled : 20:20) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 0.0%
H: 2.2%
C: -2.31%
report results
BioLineRx to Report 2021 Annual Results on March 16, 2022
Published: 2022-03-10 (Crawled : 16:20) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -1.32%
H: 6.67%
C: 2.0%
report results
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-11-18 (Crawled : 16:20) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 0.72%
H: 0.72%
C: -4.66%
financial results results
BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization
Published: 2021-10-13 (Crawled : 13:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 9.89%
H: 6.57%
C: -1.04%
positive results stem cell potential positive results
BioLineRx Reports First Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-05-26 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 3.05%
H: 1.32%
C: -3.95%
financial results results
BioLineRx to Report First Quarter 2021 Results on May 26, 2021
Published: 2021-05-20 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -1.01%
H: 9.49%
C: 7.8%
results
BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients
Published: 2021-05-04 (Crawled : 11:00) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: 53.29%
H: 29.65%
C: -0.2%
bone positive results phase 3 trial topline
BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Published: 2020-11-23 (Crawled : 15:49) - ir.biolinerx.com
BLRX | $0.6564 2.55% 2.48% 190K
|
Health Technology
|
| O: -8.33%
H: 3.93%
C: -5.79%
financial results results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.